MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Obesity-Related Heart Failure and Type 2 Diabetes

A new study led by Dr. Mikhail Kosiborod, cardiologist and vice president of research at Saint Luke’s Mid America Heart Institute, found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.

The results of the STEP-HFpEF DM trial were presented at the American College of Cardiology Scientific Session and published in the New England Journal of Medicine.

See some of the national media coverage on the study's findings below.

Related Content

Apr. 8, 2024

CNN: Weight-Loss Drug Wegovy Offers Benefits for People with Diabetes and Common Form of Heart Failure, Study Finds

The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.
Apr. 8, 2024

Good Morning America: New Report on the Effect of Weight Loss Drugs on Heart Disease

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.